A collaborative replication across top US labs
In a rare display of scientific cooperation, five research groups from UC Berkeley, UCSF and Stanford joined forces to repeat a mouse experiment that had previously hinted at lasting antidepressant‑like benefits of psilocybin, the psychoactive compound found in magic mushrooms. By standardising the dosage, behavioural batteries and timing, the teams aimed to determine whether the earlier positive signals would survive a multi‑lab scrutiny.
Why the joint effort mattered
Individual rodent studies on psychedelics have produced a patchwork of results, some suggesting reduced anxiety, others reporting no change. Small sample sizes and subtle methodological differences can inflate the appearance of efficacy, a problem that mirrors the broader reproducibility crisis in biomedical research. By pooling data from five independent laboratories, the investigators hoped to cut through the noise and reveal any robust, reproducible effect.
Experimental design at a glance
All participating labs administered an identical intraperitoneal injection of psilocybin to adult mice and then subjected the animals to a suite of behavioural assays. These included the open‑field test (measuring willingness to explore a bright arena), the forced‑swim test (gauging despair‑like immobility), a conditioned fear response, and a social interaction task that evaluates the drive to seek conspecifics. The same timeline was followed: observations were recorded one day after dosing, with additional short‑term checks at ten minutes and one hour post‑injection.
Short‑term reactions were evident
Across every laboratory, the mice displayed a characteristic “head‑twitch” response within minutes of receiving the drug – a well‑known physiological marker of serotonergic psychedelic activity. Ten minutes after injection, the animals were paradoxically more anxious, venturing less into the open field and showing heightened avoidance of the conditioned sound. These acute effects were consistent and reproducible, providing a reliable foothold for future circuit‑mapping studies.
No enduring behavioural shift
When the researchers re‑evaluated the mice 24 hours later, the picture changed dramatically. None of the five labs observed a statistically significant reduction in anxiety‑like behaviour, depressive‑like immobility, or increased sociability compared with control groups that received a saline injection. One previously reported finding – that adult mice could regain a youthful propensity for social play after psilocybin – was not replicated in any of the sites.
Implications for psychedelic research
The outcome underscores a crucial lesson: isolated positive results from small rodent cohorts should be interpreted with caution, especially when they are used to justify clinical optimism. As psychologist Michiel van Elk (University of Leiden) noted, the lack of a validated mouse model of human depression means that even a robust behavioural change in rodents may not translate to patients.
Calls for broader collaboration
Despite the disappointing long‑term findings, the study demonstrates the value of coordinated, multi‑site replication. By revealing which effects are fleeting and which, if any, are durable, such collaborations can sharpen the focus of mechanistic investigations and prevent the literature from becoming overly rosy. The authors advocate for more joint efforts in the psychedelic field to separate genuine therapeutic signals from artefacts of experimental design.